4 completed. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
Follow Immunoglobulin A Nephropathy: new trials by email Literature Review of Immunoglobulin A Nephropathy trials Research Report on Immunoglobulin A Nephropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy Atrasentan, Placebo - IgA Nephropathy, Immunoglobulin A Nephropathy | Phase 2 | Completed | Novartis Pharmaceuticals | 54 | 2023-07-20 | 2026-07-20 |
| A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN Sparsentan - Immunoglobulin A Nephropathy | Phase 2 | Completed | Travere Therapeutics, Inc. | 48 | 2023-05-19 | 2025-11-20 |
| Safety and Efficacy Study of VIS649 for IgA Nephropathy Dose-Placebo, Low Dose-VIS649, Medium Dose-VIS649 - Immunoglobulin A Nephropathy, Glomerular Disease | Phase 2 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 155 | 2020-07-20 | 2026-04-24 |
| Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade CCX168 - Immunoglobulin A Nephropathy | Phase 2 | Completed | Amgen | 7 | 2015-03-27 | 2025-03-13 |
Glomerulonephritis, IGA (4) · Glomerulonephritis (2) · Kidney Diseases (2) · Autoimmune Diseases (1) · Immune System Diseases (1) · Nephritis (1) · Proteinuria (1) · Renal Insufficiency, Chronic (1) · Urologic Diseases (1)
Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Male Urogenital Diseases (4) · Urogenital Diseases (4) · Autoimmune Diseases (3) · Immune System Diseases (3) · Nephritis (3) · Urologic Diseases (3) · Glomerulonephritis (2) · Kidney Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Chronic Disease (1) · Disease Attributes (1) · Pathologic Processes (1) · Renal Insufficiency (1)
Atrasentan (1) · avacopan (1) · sparsentan (1)
Amgen (1) · Novartis Pharmaceuticals (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Travere Therapeutics, Inc. (1)
United States (4) · Australia (2) · Hong Kong (2) · Malaysia (2) · South Korea (2) · Spain (2) · Brazil (1) · Canada (1) · India (1) · Japan (1) · Philippines (1) · Singapore (1) · Sri Lanka (1) · Sweden (1) · Taiwan (1)
Asher Schachter, M.D. (1) · Radko Komers, MD, PhD (1)
PMID 38299639, PMID 37916620, PMID 41904616, PMID 42275148
2014 (1), 2019 (1), 2023 (1)